The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression

Biomedicine and Pharmacotherapy

Volumn 95, Issue , 2017, Pages 1574-1579

  Wu, Zhenqian ^a   Hu, Zedong ^a   Han, Xiaodong ^a   Li, Zhongnan ^a   Zhu, Qingchao ^a   Wang, Yu ^a   Zheng, Qi ^a   Yan, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

ABT 26; BET bromodomain inhibitor; Colorectal cancer cells; miR 1271 5p

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; MICRORNA; MICRORNA 1271-5P; MYC PROTEIN; NAVITOCLAX; PROTEIN MCL 1; PROTEIN NOXA; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; ANILINE DERIVATIVE; AZEPINE DERIVATIVE; MIRN1271 MICRORNA, HUMAN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; SULFONAMIDE; TRIAZOLE DERIVATIVE;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL KILLING; CELL VIABILITY; COLORECTAL CANCER CELL LINE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HCT 15 CELL LINE; HT-29 CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SW620 CELL LINE; TRANSCRIPTION REGULATION; COLORECTAL TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANILINE COMPOUNDS; APOPTOSIS; AZEPINES; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SULFONAMIDES; TRIAZOLES;

EID: 85029669800     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.09.087     Document Type: Article

References (44)

1. Aghagolzadeh, P., Radpour, R., New trends in molecular and cellular biomarker discovery for colorectal cancer. World J. Gastroenterol. 22:25 (2016), 5678–5693.
2. Moriarity, A., et al. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther. Adv. Med. Oncol. 8:4 (2016), 276–293.
3. Huang, C.Y., Yu, L.C., Pathophysiological mechanisms of death resistance in colorectal carcinoma. World J. Gastroenterol. 21:41 (2015), 11777–11792.
4. Risberg, K.et al., Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer, 16(1), 2016, 531.
5. Ye, L., et al. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells. Tumour Biol. 36:5 (2015), 3447–3455.
6. Kitamura, S., et al. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br. J. Cancer 83:5 (2000), 668–673.
7. Tong, J., et al. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 36:6 (2017), 787–796.
8. Lessene, G., Czabotar, P.E., Colman, P.M., BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7:12 (2008), 989–1000.
9. Vogler, M., et al. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 16:3 (2009), 360–367.
10. Tse, C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:9 (2008), 3421–3428.
11. Shao, H., et al. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. Mol. Cancer Ther. 12:12 (2013), 2640–2650.
12. Faber, A.C., et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 112:11 (2015), E1288–96.
13. Modugno, M., et al. Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Exp. Cell Res. 332:2 (2015), 267–277.
14. Zheng, L., et al. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 309:1 (2011), 27–36.
15. Zhang, C., et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol. Cancer Ther. 10:7 (2011), 1264–1275.
16. Chen, S., et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67:2 (2007), 782–791.
17. Adams, J.M., Cory, S., The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:9 (2007), 1324–2337.
18. Wang, W., et al. MCL-1 degradation mediated by JNK activation via MEKK1/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189. Mol. Cancer Ther. 13:6 (2014), 1480–1491.
19. Yang, Z., He, N., Zhou, Q., Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 28:3 (2008), 967–976.
20. Filippakopoulos, P., et al. Selective inhibition of BET bromodomains. Nature 468:7327 (2010), 1067–1073.
21. Dang, C.V., MYC on the path to cancer. Cell 149:1 (2012), 22–35.
22. Lee, D.H., et al. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int. J. Cancer 136:9 (2015), 2055–2064.
23. Borbely, G., et al. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget 6:32 (2015), 33623–33635.
24. Wang, W., et al. TRAF family member-associated NF-kappaB activator (TANK) inhibits genotoxic nuclear factor kappaB activation by facilitating deubiquitinase USP10-dependent deubiquitination of TRAF6 ligase. J. Biol. Chem. 290:21 (2015), 13372–13385.
25. Zhang, Z., et al. MT119: a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. Int. J. Cancer 129:1 (2011), 214–224.
26. Shinoura, N., et al. Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 18:41 (1999), 5703–5713.
27. Tromp, J.M., et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin. Cancer Res. 18:2 (2012), 487–498.
28. Lucas, K.M., et al. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin. Cancer Res. 18:3 (2012), 783–795.
29. Gomez-Bougie, P., et al. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem. Biophys. Res. Commun. 413:3 (2011), 460–464.
30. Ferri, E., Petosa, C., McKenna, C.E., Bromodomains Structure, function and pharmacology of inhibition. Biochem. Pharmacol. 106 (2016), 1–18.
31. Zhao, X., et al. An improved PMF scoring function for universally predicting the interactions of a ligand with protein: DNA, and RNA. J. Chem. Inf. Model. 48:7 (2008), 1438–1447.
32. Wasserman, W.W., Sandelin, A., Applied bioinformatics for the identification of regulatory elements. Nat. Rev. Genet. 5:4 (2004), 276–287.
33. Konopleva, M., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:5 (2006), 375–388.
34. Tahir, S.K., et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67:3 (2007), 1176–1183.
35. van Delft, M.F., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:5 (2006), 389–399.
36. Airiau, K., et al. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells. Oncotarget 7:1 (2016), 845–859.
37. Chen, Q., et al. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget 6:28 (2015), 25883–25896.
38. Wang, C.et al., Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. PLoS One, 10(3), 2015, e0120913.
39. Wu, S.Y., Chiang, C.M., The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282:18 (2007), 13141–13145.
40. Mertz, J.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 108:40 (2011), 16669–16674.
41. Niu, J., et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35:10 (2016), 1302–1313.
42. Xue, J., et al. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene 35:4 (2016), 448–458.
43. Liu, H., et al. miR-1271 inhibits migration: invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 472:2 (2016), 346–352.
44. Wang, Y., Xu, L., Jiang, L., miR-1271 promotes non-small-cell lung cancer cell proliferation and invasion via targeting HOXA5. Biochem Biophys Res Commun 458:3 (2015), 714–719.